Category Archives: Hypertension

By: Express News Service | Mumbai | December 16, 2020 11:50:12 pm State officials said while it will be possible to draw a list of those under treatment at government centres, collating data from the private sector might pose a challenge. (Representational) MAHARASHTRA HAS diagnosed at least 9.07 lakh diabetic and 13.44 lakh hypertension patients since 2011, when it began screening and treating the two lifestyle disorders. These two pools will now be part of a high priority group that will be vaccinated against Covid-19 in the third phase Continue reading →

DALLAS--(BUSINESS WIRE)--Southwestern Health Resources (SWHR), the clinically integrated network of UT Southwestern and Texas Health Resources, has been recognized by the American Heart Association (AHA) and American Medical Association (AMA) for its commitment to helping improve blood pressure (BP) control rates among the patient populations it serves, earning Gold, the highest level recognition, as part of the 2020 Target: BP Recognition Program. The Gold Award recognizes practices that have 70% or more of their adult patient population with high BP controlled Continue reading →

The research report on Hypertension Drugs market Added by Market Study Report, LLC, proposes a comprehensive study on the recent industry trends. In addition, the report presents a detailed abstract of the growth statistics, revenue estimation, and market valuation, and also highlights the state of the competitive spectrum and expansion strategies adopted by major industry players. Continue reading →

Objectives:To explore the prognostic value of pre-specified comorbidities on treatment outcomes in PsA, and to compare baseline data with cutaneous psoriasis without arthritis and healthy controls (HC). Methods:Patients initiating conventional synthetic/biological disease-modifying antirheumatic drugs were enrolled in this clinical observational cohort study, and data on comorbidities, and clinical and patient-reported outcomes were retrieved at baseline and after 4 months. Pearsons chi-squared tests were performed to investigate the prognostic value of pre-specified comorbidities and achievement of ACR20, DAPSA50 and MDA Continue reading →

Matt J. Granato, LL.M., MBA, joins the Pulmonary Hypertension Association Jan. Continue reading →

Saturday December 19 2020 Advertisement By Asuman Bisiika The Koran and the Bible are the most dominant books of coded socio-moral instruction in Uganda. These books teach us that life and death are two sides of the same coin. Continue reading →

December 15, 2020 02:00 ET | Source: Quantum Genomics Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greece PARIS and NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- QuantumGenomics (EuronextGrowth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Faran to develop and commercialize firibastat in Greece. Continue reading →

December 17, 2020 16:04 ET | Source: Virgin Pulse Streamlining Access to Third-Party Partner Programs through Virgin Pulses Homebase for Health Unlocks Significant Value, Increases Benefits Utilization and Drives Health Outcomes that Matter for Clients and Members; Allows Members to Manage their Health and Wellbeing in One Place PROVIDENCE, R.I., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital health and wellbeing solutions, today announced the addition of 16 new partners across 11 critical health and wellbeing areas to its Adaptive Partner Network. Continue reading →

Downtown Silver Spring-based United Therapeutics has received an FDA designation that helps to expand the company beyond its core business, according to areportfrom the Washington Business Journal. According to WBJ, the Food and Drug Administration last week had awarded orphan drug status to treprostinil. The active ingredient in several of its products, treprostinil has now been permitted to treat patients with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that scars the lungs and impedes breathing. Continue reading →

A new review is taking a look at the rationale and evidence for using a multidrug approach in pulmonary arterial hypertension (PAH), which the researcher says has a trajectory of progress that is exemplary among cardiopulmonary diseases. There are currently 14 approved therapies for the treatment of PAH, all of which target nitric oxide signaling (soluble guanylyl cyclase stimulator and phosphodiesterase type-V inhibitor [PDE-Vi] classes), the endothelin receptor axis (selective ETA and non-selective ETA/B antagonists), and the prostacyclin pathways (prostaglandin-I2 replacement or counter-receptor agonism). When it comes to multidrug treatment in PAH using the 14 available therapies, they are either used sequentially or combined upfront. Continue reading →